Table 1 Baseline characteristics
From: Safety and feasibility of oral immunotherapy to multiple allergens for food allergy
Multiple food allergy group | Single peanut allergy group | |
|---|---|---|
Number of participants | 25 | 15 |
Median Age in yrs. (range) | 8 (4–25) | 10 (5–46) |
Male | 14 (56%) | 8 (53%) |
Coexisting atopic disease | ||
Atopic Dermatitis | 17 (68%) | 8 (53%) |
Allergic Rhinitis | 13 (52%) | 9 (60%) |
Asthma | 17 (68%) | 10 (66%) |
Baseline testing to peanut (median and range) | ||
SPT in mm | 15 (7–25.5) | 12 (7–22) |
Specific IgE in kUA/L | 90.4 (2.43-100) | 80 (3.66-100) |
DBPCFC step eliciting symptoms (mg protein) | 50 (0.1-100) | 25 (1.6-100) |
Symptoms upon peanut DBPCFC | ||
Skin | 20 (80%) | 12 (80%) |
Upper airways | 18 (72%) | 12 (80%) |
GI | 17 (68%) | 12 (80%) |
Lower airways | 6 (24%) | 3 (20%) |
Other food allergies meeting DBPCFC criteria for inclusion | ||
Walnut | 14 (56%) | N/A |
Cashew | 13 (52%) | N/A |
Pecan | 7 (28%) | N/A |
Milk | 7 (28%) | N/A |
Egg | 6 (24%) | N/A |
Sesame | 6 (24%) | N/A |
Almond | 5 (20%) | N/A |
Hazelnut | 3 (12%) | N/A |
Number of food in mix | ||
2 | 6 (24%) | N/A |
3 | 8 (32%) | N/A |
4 | 5 (20%) | N/A |
5 | 6 (24%) | N/A |